“however, when you look at where we will likely be in 2024, we will likely have the majority of our business in either zero or one step edit position.”

In context

“t Bansal: Great, thank you for taking my question. My question is regarding--my question is related to Sotyktu, because it seems like in the prepared remarks, you mentioned that Sotyktu contracting to zero step edits may run to 2025, and you mentioned because there are some changes in the immunologic contracting market. Can you please help us understand that a little bit better - what are these changes, and how should we think about the long-term net pricing for this category? Thank you. Adam Lenkowsky: Yes Mohit, thanks for the question. I’ll take that one. As I said, we are working to improve significantly our formulary access in 2024, and as I said, we have approximately 80% of lives today that are not covered on Sotyktu. We expect that to change dramatically as we move into next year; however, when you look at where we will likely be in 2024, we will likely have the majority of our business in either zero or one step edit position. When we’re talking to PBMs, and the reason why we’re talking a little bit about 2025, PBMs are really thinking about different ways to manage the PSO class, as well as the broader immunology class, with now more and more bio-similiar Humira coming into the market, and so those decisions have not yet been finalized for 2025. But as I stated, we’re very confident that we will see a significantly broader access position next year, so we’ll go from non-covered to being covered, which will be a really nice growth opportunity for Sotyktu as we move into early next year. Tim Power: Thanks Adam. Let’s go to the next question, please. Operator: Yes, and that comes from Olivia Brayer with Cantor Fitzgerald. Olivia Brayer: Hey, good morning, and thank you for the question. M&A has obviously been som”